Skip to main content
Midas Edge

Anteris Technologies Global Corp

For the period ended Dec 31, 2024. Filed Mar 12, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 12, 2025

AVR$5.89-0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits, Financial Statement Schedules

Item 15.Exhibits, Financial Statement Schedules.

The following documents are filed as part of this report:

1.Financial Statements

Information in response to this Item is included in Part II, Item 8 of this Form 10-K.

2.Financial Statement Schedules

All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.

3.Exhibits

The following is a list of exhibits filed or furnished as part of this Form 10-K.

Exhibit Index

Exhibit Number · Description · Incorporated by Reference · Filed
Form · Date · Number · Herewith
2.1 †Scheme Implementation Deed, dated August 13, 2024, by and between Anteris Technologies Global Corp. and Anteris Technologies LtdS-111/22/20242.1
3.1Second Amended and Restated Certificate of Incorporation of Anteris Technologies Global Corp.8-K12/16/20243.1
3.2Amended and Restated Bylaws of Anteris Technologies Global Corp.8-K12/16/20243.2
4.1Reference is made to Exhibits 3.1 through 3.2X
4.2 †^Convertible Securities Agreement, dated October 31, 2024, between Anteris Technologies Ltd and Obsidian Global GP, LLCS-111/22/20244.2
4.3Description of Registrant’s SecuritiesX
10.1 +Anteris Technologies Global Corp. Equity Incentive PlanS-111/22/202410.1
10.2 +Admedus Ltd Employee Long Term Incentive PlanS-812/16/202499.2
10.3 +Anteris Technologies Ltd Employee Incentive PlanS-812/16/202499.3
10.4+Form of Indemnification Agreement for Directors and OfficersS-111/22/202410.2
10.5 #†^Development Agreement, dated April 18, 2023, by and between v2vmedtech, inc. and Anteris Technologies CorporationS-111/22/202410.3
Exhibit NumberDescriptionIncorporated by ReferenceFiled
FormDateNumberHerewith
10.6 #^License Agreement, dated October 11, 2019, among Admedus Ltd, Admedus Regen Pty Ltd, Admedus Biomanufacturing Pty Ltd and LeMaitre Vascular, Inc.S-111/22/202410.4
10.7 #†^Transition Services Agreement, dated October 11, 2019, among Admedus Ltd, Admedus Regen Pty Ltd, Admedus Biomanufacturing Pty Ltd and LeMaitre Vascular, Inc.S-1/A12/9/202410.5
10.8 #Amendment No. 1 to Transition Services Agreement, dated August 28, 2021, among Anteris Technologies Ltd, Admedus Regen Pty Ltd, Admedus Biomanufacturing Pty Ltd and LeMaitre Vascular, Inc.S-111/22/202410.6
10.9 #Amendment No. 2 to Transition Services Agreement, dated December 19, 2022, among Anteris Technologies Ltd, Admedus Regen Pty Ltd, Admedus Biomanufacturing Pty Ltd and LeMaitre Vascular, Inc.S-111/22/202410.7
10.10 #^Amendment No. 3 to Transition Services Agreement, dated September 18, 2023, among Anteris Technologies Ltd, Anteris Aus Operations Pty Ltd and LeMaitre Vascular, Inc.S-111/22/202410.8
10.11 #†^Supply and Quality Agreement, dated May 15, 2024, by and between Anteris Aus Operations Pty Ltd and Harvey Industries Group Pty LtdS-111/22/202410.9
10.12 †^Second Amended and Restated Supply and License Agreement, dated June 1, 2018, between 4C Medical Technologies, Inc. and Admedus CorporationS-111/22/202410.10
10.13 †^Amendment No. 1 to Second Amended and Restated Supply and License Agreement, dated March 5, 2024, between 4C Medical Technologies, Inc. and Anteris Technologies CorporationS-111/22/202410.11
10.14 #†^Supply and Quality Agreement, dated November 16, 2021 between Anteris Technologies Corporation and Aran Biomedical TeorantaS-111/22/202410.12
10.15 ^Supplier Quality Agreement, dated February 15, 2024, between Taurus Engineering and Manufacturing, Inc. and Anteris Technologies CorporationS-111/22/202410.13
10.16 #†^First Amended and Restated Services Agreement, dated February 21, 2021, by and between NPX Medical, LLC and Anteris Technologies CorporationS-111/22/202410.14
Exhibit NumberDescriptionIncorporated by ReferenceFiled
FormDateNumberHerewith
10.17Amendment No. 1 to First Amended and Restated Services Agreement, dated March 24, 2024, by and between NPX Medical, LLC and Anteris Technologies CorporationS-111/22/202410.15
10.18 #†^Master Services Agreement, dated June 1, 2021, by and between Anteris Technologies Corporation and Switchback Medical LLCS-111/22/202410.16
10.19 #†^Sublease Agreement, dated March 1, 2022, by and between Switchback Medical LLC and Anteris Technologies CorporationS-111/22/202410.17(a)
10.20 #^Sublease Amending Agreement, dated February 24, 2023, by and between Switchback Medical LLC and Anteris Technologies CorporationS-111/22/202410.17(b)
10.21 #^Sublease Amending Agreement, dated August 18, 2023, by and between Switchback Medical LLC and Anteris Technologies CorporationS-111/22/202410.17(c)
10.22 #^Sublease Amending Agreement, dated May 28, 2024, by and between Switchback Medical LLC and Anteris Technologies CorporationS-111/22/202410.17(d)
10.23 †^Combined Bioinformatics Master Services Agreement, dated September 1, 2021, by and between Anteris Technologies Corporation and Cardiovascular Research FoundationS-111/22/202410.18
10.24 #†^Lease of Part 26 Harris Road, Malaga, dated February 1, 2009, by and between Giacomel Pty Ltd, Verigen Australia Pty Ltd and Genzyme CorporationS-111/22/202410.19(a)
10.25 #†Deed of Variation of Lease, dated June 23, 2014, among Giacomel Pty Ltd, Admedus Biomanufacturing Pty Ltd, Genzyme Corporation and Admedus LtdS-111/22/202410.19(b)
10.26 #Deed of Extension and Variation, dated February 19, 2019, by and between Giacomel Pty Ltd, Admedus Biomanufactuing Pty Ltd and Admedus LtdS-111/22/202410.19(c)
10.27Deed of Assignment of Lease, dated March 28, 2023 by and between Giacomel Pty Ltd, Admedus Biomanufacturing Pty Ltd, Admedus Regen Pty Ltd and Anteris Technologies LtdS-111/22/202410.19(d)
10.28 #Deed of Variation of Lease, dated June 12, 2023, by and between Giamocel Pty Ltd, Anteris Aus Operations Pty Ltd and Anteris Technologies LtdS-111/22/202410.19(e)
Exhibit NumberDescriptionIncorporated by ReferenceFiled
FormDateNumberHerewith
10.29 #Deed of Extension and Variation of Lease, dated February 13, 2024, among Giacomel Pty Ltd, Anteris Aus Operations Pty Ltd and Anteris Technologies LtdS-111/22/202410.19(f)
10.30 #†^+Professional Services Agreement, dated September 3, 2021, between Anteris Technologies Corporation and Christopher Meduri, M.D.S-111/22/202410.20(a)
10.31 #†+Amendment No. 1 to Professional Services Agreement, dated May 1, 2023, between Anteris Technologies Corporation and Christopher Meduri, M.D.S-111/22/202410.20(b)
10.32 +Executive Service Agreement, dated December 1, 2019, between Admedus Corporation and Wayne PatersonS-111/22/202410.21
10.33 #†+Employee Agreement, dated December 1, 2019, between Admedus Limited ACN 088 221 078 and Matthew McDonnellS-111/22/202410.22
10.34 †+Executive Service Agreement, dated May 10, 2017, between Admedus Corporation and David St DenisS-111/22/202410.23
10.35 +^Amended and Restated Employment Agreement, dated November 18, 2024, by and between Anteris Technologies Global Corp. and Wayne PatersonS-111/22/202410.24
10.36 +†^Contract of Employment, dated November 19, 2024, by and between Anteris Technologies Ltd and Matthew McDonnellS-111/22/202410.25
10.37 +^Amended and Restated Employment Agreement, dated November 19, 2024, by and between Anteris Technologies Global Corp. and David St DenisS-111/22/202410.26
10.38 #Anteris Technologies Global Corp. Non-Employee Director Compensation PolicyS-111/22/202410.27
10.39 #†Contribution and Stock Purchase Agreement, dated April 18, 2023, by and among Anteris Technologies Corporation, v2vmedtech, inc., Dr. Vinayak Bapat, Urmi Bapat, Shalaka Bapat, Susheel Kodali, Michael McDonald and Christopher MeduriS-1/A12/9/202410.28
14.1Code of Business Conduct and EthicsX
19.1Insider Trading and Securities Dealing PolicyX
21.1Subsidiaries of the RegistrantS-111/22/202421.1
Exhibit NumberDescriptionIncorporated by ReferenceFiled
FormDateNumberHerewith
23.1(a)Consent of Independent Registered Public Accounting Firm for Anteris Technologies Global Corp.X
23.2Consent for Future Market Insights, Inc.X
24.1Power of Attorney (included in the signature page hereto)X
31.1Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X
31.2Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X
32.1*Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
97.1Compensation Clawback PolicyX
*This certification attached as Exhibit 32.1 that accompanies this Form 10-K, is deemed furnished and not filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.
#Certain identified information has been excluded from this exhibit pursuant to Rule 601(b)(10) of Regulation S-K because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.
†Certain information in this exhibit has been redacted pursuant to Item 601(a)(6) of Regulation S-K.
^Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Anteris Technologies Global Corp. agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.
+Management contract or compensatory plan, contract or arrangement.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.